Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD - HCPLive
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
News|Articles|October 16, 2026 Mucus plugging is increasingly recognized as a pathophysiological feature of chronic obstructive pulmonary disease (COPD), associated in prior literature with worse symptoms, poorer quality of life, higher exacerbation risk, and increased mortality. A late-breaking integrated analysis of the replicate phase 3 OBERON and TITANIA trials introduced a segmental mucus plug score, a standardized metric scoring 18 lung segments for the presence or absence of a plug using a centralized double-read CT paradigm.1Nearly 79% of the imaging cohort had at least 1 mucus-plugged segment at baseline, and these patients had worse lung function, higher symptom burden, and more prior exacerbations than those without plugging. Tozorakimab produced a dose-dependent reduction in segmental mucus plug score at week 52, with both current and former smokers contributing to the overall effect.
This article is an excerpt. To read the full content, visit the original source. HCPLive
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!